BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1426 related articles for article (PubMed ID: 35144972)

  • 21. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis.
    Yau K; Chan CT; Abe KT; Jiang Y; Atiquzzaman M; Mullin SI; Shadowitz E; Liu L; Kostadinovic E; Sukovic T; Gonzalez A; McGrath-Chong ME; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Levin A; Blake PG; Colwill K; Gingras AC; Hladunewich MA
    CMAJ; 2022 Feb; 194(8):E297-E305. PubMed ID: 35115375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.
    Grupper A; Sharon N; Finn T; Cohen R; Israel M; Agbaria A; Rechavi Y; Schwartz IF; Schwartz D; Lellouch Y; Shashar M
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1037-1042. PubMed ID: 33824157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.
    Lacson E; Argyropoulos CP; Manley HJ; Aweh G; Chin AI; Salman LH; Hsu CM; Johnson DS; Weiner DE
    J Am Soc Nephrol; 2021 Nov; 32(11):2735-2742. PubMed ID: 34348908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
    Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
    Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.
    Uprichard SL; O'Brien A; Evdokimova M; Rowe CL; Joyce C; Hackbart M; Cruz-Pulido YE; Cohen CA; Rock ML; Dye JM; Kuehnert P; Ricks KM; Casper M; Linhart L; Anderson K; Kirk L; Maggiore JA; Herbert AS; Clark NM; Reid GE; Baker SC
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
    Hirai K; Shimotashiro M; Sonoda T; Okumura T; Ookawara S; Morishita Y
    Clin Exp Nephrol; 2022 Sep; 26(9):925-932. PubMed ID: 35426594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
    Stampfer SD; Goldwater MS; Jew S; Bujarski S; Regidor B; Daniely D; Chen H; Xu N; Li M; Green T; Fung E; Aquino E; Swift R; Eshaghian S; Preugschat K; Feinstein AJ; Spektor TM; Berenson JR
    Leukemia; 2021 Dec; 35(12):3534-3541. PubMed ID: 34326466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination and COVID-19 Dynamics in Dialysis Patients.
    El Karoui K; Hourmant M; Ayav C; Glowacki F; Couchoud C; Lapidus N;
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):395-402. PubMed ID: 35144970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Third vaccine boosters and anti-S-IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma.
    Wang CW; Huang CF; Jang TY; Yeh ML; Liang PC; Wei YJ; Hsu PY; Huang CI; Hsieh MY; Lin YH; Huang JF; Dai CY; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2024 May; 40(5):477-488. PubMed ID: 38363080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
    Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S
    JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
    Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
    Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serial SARS-CoV-2 antibody titers in vaccinated dialysis patients: prevalence of unrecognized infection and duration of seroresponse.
    Hsu CM; Weiner DE; Manley HJ; Miskulin D; Ladik V; Frament J; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    medRxiv; 2023 Mar; ():. PubMed ID: 36993760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.